Market Place
Sourcing Support
Nimbus Presents Updated HPK1 Inhibitor Data at SITC 2024
07 Nov 2024 //
BUSINESSWIRE
Nimbus Therapeutics Presents Preclinical Data on NTX-452
23 Oct 2024 //
BUSINESSWIRE
Nimbus To Present Werner Syndrome Helicase Program Data
09 Oct 2024 //
BUSINESSWIRE
Nimbus Hpk1 Solid Tumors Positive: Phase 1/2 Monotherapy Data At Asco24
23 May 2024 //
BUSINESSWIRE
After $4B Takeda deal, Nimbus lays out
23 May 2024 //
ENDPTS
Nimbus Appoints Anita Scheuber As Oncology Therapeutic Head
07 May 2024 //
BUSINESSWIRE
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
12 Mar 2024 //
BUSINESSWIRE
Nimbus Announces Expansion of Its Immunology Drug Discovery Pipeline
05 Jan 2024 //
BUSINESSWIRE
Anagenex and Nimbus Announce a Multi-Target Collaboration
18 Dec 2023 //
BUSINESSWIRE
Nimbus Presents Positive Data from Clinical Trial of HPK1 Inhibitor
31 Oct 2023 //
BUSINESSWIRE
Nimbus Therapeutics Secures $210M Private Financing
06 Sep 2023 //
BUSINESSWIRE
Takeda`s $4B drug clears psoriasis in one-third of patients
20 Mar 2023 //
FIERCE BIOTECH
Schrödinger Receives $111.3M Distribution from Sale of Nimbus’s TYK2 to Takeda
14 Feb 2023 //
BUSINESSWIRE
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
09 Feb 2023 //
BIOSPACE
Nimbus CEO Jeb Keiper on negotiating a $4B deal
16 Dec 2022 //
BIOPHARMADIVE
Japan`s Takeda to buy Nimbus` psoriasis drug for as much as $6 bln
14 Dec 2022 //
REUTERS
Nimbus Therapeutics reports positive data from psoriasis therapy trial
01 Dec 2022 //
CLINICALTRIALSARENA
Nimbus Announces +ve Topline Results for Ph2b Trial Allosteric TYK2 in Psoriasis
30 Nov 2022 //
BUSINESSWIRE
Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu
30 Nov 2022 //
FIERCEBIOTECH
Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as CMO
26 Oct 2022 //
BUSINESSWIRE
Lilly, Nimbus ink $496M biobucks deal
12 Oct 2022 //
FIERCEBIOTECH
Nimbus raises $125m to test drug in psoriasis, lupus, and other diseases
13 Sep 2022 //
BOSTONGLOBE
Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor
24 Aug 2022 //
BUSINESSWIRE
Nimbus Presents Addn Data from PI Studies of Oral Allosteric TYK2 Inhibitor
19 May 2022 //
BUSINESSWIRE
Nimbus Tx Presents Preclinical Data on Cbl-b Inhibitor at AACR
08 Apr 2022 //
BUSINESSWIRE
Nimbus Shows Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD
25 Mar 2022 //
BUSINESSWIRE
Nimbus Therapeutics Shares Update on Discovery Efforts; Expands Leadership Team
03 Feb 2022 //
BUSINESSWIRE
Nimbus Tx Announces Expansion of Oral Allosteric TYK2 Inhibitor Program
06 Jan 2022 //
BUSINESSWIRE
Nimbus Therapeutics begins dosing in Phase I/II solid tumours therapy trial
15 Nov 2021 //
CLINICALTRIALSARENA
Nimbus Initiates Dosing in Phase 1/2 Study of a Highly Selective HPK1 Inhibitor
12 Nov 2021 //
BUSINESSWIRE
Nimbus Therapeutics Publishes Structural Analysis Highlighting Mechanisms CTPS1
30 Sep 2021 //
BUSINESSWIRE
Rosana Kapeller raises $77M in bid to make repeatome drugs a reality
14 Sep 2021 //
ENDPTS
Nimbus Doses First Patient in PIIb Study of Oral TYK2 Inhibitor in Psoriasis
14 Sep 2021 //
BUSINESSWIRE
Nimbus, Schrödinger extend deal to find new therapeutics for select targets
12 Aug 2021 //
PHARMABIZ
Nimbus, Schrödinger extend deal to find new therapeutics for select targets
12 Aug 2021 //
PHARMABIZ
Nimbus Therapeutics and Schrödinger collaborate to Discover Novel Therapeutics
12 Aug 2021 //
BUSINESSWIRE
Nimbus raises $105M for multifront TYK2 clinical trial program
13 Jul 2021 //
FIERCEBIOTECH
Flush with cash, computational chemistry pioneer Nimbus considers next steps
13 Jul 2021 //
ENDPTS
Nimbus Therapeutics Announces $105 Million Private Financing
13 Jul 2021 //
BUSINESSWIRE
Nimbus Presents In Vivo Data Showing Single-Agent and Activity of HPK1
09 Apr 2021 //
BUSINESSWIRE
Nimbus Presents In Vivo Data Showing Single-Agent and Activity of HPK1
08 Apr 2021 //
BUSINESSWIRE
Nimbus to Present Updated Preclinical Data From HPK1 Inhibitor Program
05 Nov 2020 //
BUSINESSWIRE
Nimbus to Present New Data on Novel HPK1 Inhibitors at Scientific Conferences
22 Oct 2020 //
BIOSPACE
Nimbus nets $60M to propel 2 lead programs through the clinic
13 Oct 2020 //
FIERCE BIOTECH
Scott Edmondson leaves AstraZeneca, starts new chapter at Nimbus; With IPO
04 Sep 2020 //
ENDPTS
Nimbus Therapeutics nabs AstraZeneca`s Edmondson
01 Sep 2020 //
FIERCE BIOTECH
Nimbus Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition
22 Jun 2020 //
BUSINESSWIRE
Nimbus Therapeutics to Host Seminar on Preclinical Data from HPK1 Program
18 Jun 2020 //
BUSINESS WIRE
BIO: Nimbus CEO: `We`re not just a one-hit wonder`
08 Jun 2020 //
FIERCE BIOTECH
Nimbus picks 4 preclinical targets for the next chapter computational drug
08 Jun 2020 //
ENDPTS
